Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.53 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 7/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5166021 | 0.89 | PTPN1 (0.65) | PTPN1PTPN2MAPTTAS2R14KDM4E | |
| SCHEMBL5165954 | 0.87 | PTPN1 (0.53) | PTPN1PTPN2MAPT | |
| SCHEMBL5166237 | 0.79 | PTPN1 (0.50) | PTPN1PTPN2MAPT | |
| SCHEMBL5165546 | 0.79 | PTPN1 (0.65) | PTPN1PTPN2TAS2R14CXCR3 | |
| SCHEMBL5165963 | 0.79 | PTPN1 (0.49) | PTPN1PTPN2MAPT | |
| SCHEMBL5166028 | 0.78 | TAS2R14 (0.48) | MAPTPOLBTAS2R14TP53KDM4E | |
| SCHEMBL4897885 | 0.75 | MAPK10 (0.42) | MAPTSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5166705 | 0.75 | CNR1 (0.42) | PTPN1PTPN2MAPTPOLBALDH1A1 | |
| SCHEMBL5188294 | 0.75 | PTPN1 (0.75) | PTPN1PTPN2 | |
| SCHEMBL13939149 | 0.74 | TAS2R14 (0.77) | MAPTPOLBTAS2R14CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765332-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | Cengent Therapeutics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006009876-A2 | TRISUBSTITUTED NITROGEN MODULATORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135773-A1 | Trisubstituted nitrogen modulators of tyrosine phosphatases | PTPA, PTPN1, PTPRS | PTPN1 2/4885PTPN2 12/4885MAPT 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.